----- -----
Total current assets 54,700 50,041
Intangible asset, net 11,806 12,387
Property and equipment, net 11,367 13,238
Marketable securities 1,584 3,145
Other assets 3,335 969
----- ---
Total assets $82,792 $79,780
======= =======
LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT)
Accounts payable and accrued expenses $12,608 $13,136
Deferred revenue, related party 6,110 5,965
Other current liabilities 1,617 475
----- ---
Total current liabilities 20,335 19,576
Long-term obligations 33,411 17,061
Deferred revenue, related party,
net of current portion 33,607 35,790
------ ------
Total liabilities 87,353 72,427
Stockholders' equity (deficit) (4,561) 7,353
------ -----
Total liabilities and stockholders'
equity (deficit) $82,792 $79,780
======= =======
Idenix Pharmaceuticals' Contacts:
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838
'/>"/>SOURCE Idenix Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results2.
Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference3.
Idenix Pharmaceuticals Reports First Quarter Financial Results4.
Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver5.
Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference6.
Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)7.
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results8.
Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results9.
Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference10.
Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab11.
Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results